Skip to content

NLSDays – NLSInvest: What are international investors are looking for?

Q&A with Anna Bellmunt Associate, Asabys Partners

This is your first time coming to Nordic Life science days and our pre-event NLS Invest. What attracts you to the Nordics?
– We are excited to participate for the first time in NLS Days. We are interested in learning more about the science that comes from the Nordic countries and we are looking forward to interacting with top innovative companies. As a European healthcare investor, we like to meet entrepreneurs, executives and investors from all over the world, to share our experiences, activities, goals and visions. It is of outmost importance that we all collaborate towards the evolution of the healthcare industry, to ensure constant innovation providing high-quality care and affordable access to the global population

What is it that you are looking for among the companies present?
– Asabys is a Venture Capital firm based in Barcelona that invests across the board in human healthcare. We are open to investing in Biopharma, Medtech and Digital therapeutic solutions. We are looking for companies that, by combining the latest and most disruptive technological advancements with top scientific and medical expertise, are able to provide new treatment solutions to unmet medical needs.

How do you perceive the development in the Nordic life science region; would you agree that it´s increasingly capturing the interest of investors?
– Yes! We have seen some Nordic companies lately that have pleasantly surprised us. The Nordics have established renown universities, research centers and hospitals, that lay the foundation for the development of high-quality scientific and medical experts, as well as the perfect environment for innovation and life science development. We are very interested in being in contact with more investment opportunities that arise from this region.for both debt and equity investors.

This website uses cookies to improve your experience. By continuing to browse, you consent to our use of cookies. View privacy policy.